TCHAKO PATCHOU, DOMINIQUE
TCHAKO PATCHOU, DOMINIQUE
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
2019 Usmani SZ1, Schjesvold F2, Oriol A3, Karlin L4, Cavo M5, Rifkin RM6, Yimer HA7, LeBlanc R8, Takezako N9, McCroskey RD10, Lim ABM11, Suzuki K12, Kosugi H13, Grigoriadis G14, Avivi I15, Facon T16, Jagannath S17, Lonial S18, Ghori RU19, Farooqui MZH19, Marinello P19, San-Miguel J20; KEYNOTE-185 Investigators. Lim A, Grigoriadis G, Walker T, Nicol A, LeBlanc R, Reece D, Elemary M, Boudreault Pedneault JS, Karlin L, Facon T, Attal M, Weisel K, Engelhardt M, Mackensen A, Quinn J, Avivi I, Cohen A, Magen-Nativ H, Benyamini N, Cavo M, Larocca A, Takezako N, Suzuki K, Kosugi H, Matsumoto M, Iida S, Ishikawa T, Kondo Y, Sunami K, Ando K, Teshima T, Chou T, Iwasaki H, Miki H, Matsumura I, Onishi Y, Izutsu K, Kizaki M, George A, Blacklock H, Simpson D, Schjesvold F, Waage A, Samoilova O, Nikitin E, Chagorova T, McDonald A, Patel M, Oriol Rocafiguera A, San Miguel Izquierdo J, Mateos M, Streetly M, Forsyth P, Jackson G, Jenkins S, Rifkin R, Yimer H, McCroskey R, Martincic D, Tarantolo S, Larson S, Faroun Y, Vaughn J, Baz R, Saylors G, Neppalli A, Raptis A, Fung H, Janosky M, Stevens D, Coleman M, Costa D, Cross S, Fanning S, Berges DF, Harris T, Zackon I, Atanackovic D, Lee K, Oliff I, Lee W, Bensinger W, Lutzky J, Baron A, Hayek F, Kirschner E, Bharany N, Overton L, Mannem S, Harroff A, Jain S, Roque T, McIntyre K, Yasencha CK, Houck W.
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
2019 Mateos, Maria-Victoria; Blacklock, Hilary; Schjesvold, Fredrik; Oriol, Albert; Simpson, David; George, Anupkumar; Goldschmidt, Hartmut; Larocca, Alessandra; Chanan-Khan, Asher; Sherbenou, Daniel; Avivi, Irit; Benyamini, Noam; Iida, Shinsuke; Matsumoto, Morio; Suzuki, Kenshi; Ribrag, Vincent; Usmani, Saad Z; Jagannath, Sundar; Ocio, Enrique M; Rodriguez-Otero, Paula; San Miguel, Jesus; Kher, Uma; Farooqui, Mohammed; Liao, Jason; Marinello, Patricia; Lonial, Sagar; KEYNOTE-183 Investigators; Nicol A, Grigoriadis G, Catalano J, LeBlanc R, Elemary M, Bahlis N, Facon T, Karlin L, Ribrag V, Attal M, Goldschmidt H, Engelhardt M, Weisel K, Mackensen A, Nagler A, Ben Yehuda D, Avivi I, Benyamini N, Magen-Nativ H, Palumbo A, Cavo M, Tobinai K, Iida S, Chou T, Suzuki K, Kosugi H, Taniwaki M, Sunami K, Matsumoto M, Ando K, Ganly P, Blacklock H, Simpson D, George A, Schjesvold F, Gjertsen B, Lahuerta J, Blade J, Oriol Rocafiguera A, Mateos M, Rodriguez-Otero P, Larson S, Atanackovic D, Devarakonda S, Bitran J, Zonder J, Morganstein N, Hay M, Chanan-Khan A, Saylors G, Kio E, Oliff I, Kirkel D, Shtivelband M, Yuen C, Yee A, Shah J, Htut M, Raza S, Chhabra S, Stiff P, Hari P, Bank B, Malek E, Gasparetto C, Faroun Y, Sherbenou D, Kreisle W, Singhal S, Rosenblatt J, Usmani S, Lee W, Safah H, Lutzky J, Suh J, Pan D, Baron A, Manges R, Steis R, Oliveira M, Moreb J, Callander N, Anz B, Raptis A, Stampleman L, Melear J, Boyd T, Garbo L, Klein L, Shao S, Lyons R, McIntyre K, Tarantolo S, Yasenchak C, Yimer H.
Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
---|---|---|---|---|---|---|
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial |
Usmani SZ1, Schjesvold F2, Oriol A3, Karlin L4, Cavo M5, Rifkin RM6, Yimer HA7, LeBlanc R8, Takez...ako N9, McCroskey RD10, Lim ABM11, Suzuki K12, Kosugi H13, Grigoriadis G14, Avivi I15, Facon T16, Jagannath S17, Lonial S18, Ghori RU19, Farooqui MZH19, Marinello P19, San-Miguel J20; KEYNOTE-185 Investigators. Lim A, Grigoriadis G, Walker T, Nicol A, LeBlanc R, Reece D, Elemary M, Boudreault Pedneault JS, Karlin L, Facon T, Attal M, Weisel K, Engelhardt M, Mackensen A, Quinn J, Avivi I, Cohen A, Magen-Nativ H, Benyamini N, Cavo M, Larocca A, Takezako N, Suzuki K, Kosugi H, Matsumoto M, Iida S, Ishikawa T, Kondo Y, Sunami K, Ando K, Teshima T, Chou T, Iwasaki H, Miki H, Matsumura I, Onishi Y, Izutsu K, Kizaki M, George A, Blacklock H, Simpson D, Schjesvold F, Waage A, Samoilova O, Nikitin E, Chagorova T, McDonald A, Patel M, Oriol Rocafiguera A, San Miguel Izquierdo J, Mateos M, Streetly M, Forsyth P, Jackson G, Jenkins S, Rifkin R, Yimer H, McCroskey R, Martincic D, Tarantolo S, Larson S, Faroun Y, Vaughn J, Baz R, Saylors G, Neppalli A, Raptis A, Fung H, Janosky M, Stevens D, Coleman M, Costa D, Cross S, Fanning S, Berges DF, Harris T, Zackon I, Atanackovic D, Lee K, Oliff I, Lee W, Bensinger W, Lutzky J, Baron A, Hayek F, Kirschner E, Bharany N, Overton L, Mannem S, Harroff A, Jain S, Roque T, McIntyre K, Yasencha CK, Houck W. |
2019-01-01 | THE LANCET. HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial | Mateos, Maria-Victoria; Blacklock, Hilary; Schjesvold, Fredrik; Oriol, Albert; Simpson, David; Ge...orge, Anupkumar; Goldschmidt, Hartmut; Larocca, Alessandra; Chanan-Khan, Asher; Sherbenou, Daniel; Avivi, Irit; Benyamini, Noam; Iida, Shinsuke; Matsumoto, Morio; Suzuki, Kenshi; Ribrag, Vincent; Usmani, Saad Z; Jagannath, Sundar; Ocio, Enrique M; Rodriguez-Otero, Paula; San Miguel, Jesus; Kher, Uma; Farooqui, Mohammed; Liao, Jason; Marinello, Patricia; Lonial, Sagar; KEYNOTE-183 Investigators; Nicol A, Grigoriadis G, Catalano J, LeBlanc R, Elemary M, Bahlis N, Facon T, Karlin L, Ribrag V, Attal M, Goldschmidt H, Engelhardt M, Weisel K, Mackensen A, Nagler A, Ben Yehuda D, Avivi I, Benyamini N, Magen-Nativ H, Palumbo A, Cavo M, Tobinai K, Iida S, Chou T, Suzuki K, Kosugi H, Taniwaki M, Sunami K, Matsumoto M, Ando K, Ganly P, Blacklock H, Simpson D, George A, Schjesvold F, Gjertsen B, Lahuerta J, Blade J, Oriol Rocafiguera A, Mateos M, Rodriguez-Otero P, Larson S, Atanackovic D, Devarakonda S, Bitran J, Zonder J, Morganstein N, Hay M, Chanan-Khan A, Saylors G, Kio E, Oliff I, Kirkel D, Shtivelband M, Yuen C, Yee A, Shah J, Htut M, Raza S, Chhabra S, Stiff P, Hari P, Bank B, Malek E, Gasparetto C, Faroun Y, Sherbenou D, Kreisle W, Singhal S, Rosenblatt J, Usmani S, Lee W, Safah H, Lutzky J, Suh J, Pan D, Baron A, Manges R, Steis R, Oliveira M, Moreb J, Callander N, Anz B, Raptis A, Stampleman L, Melear J, Boyd T, Garbo L, Klein L, Shao S, Lyons R, McIntyre K, Tarantolo S, Yasenchak C, Yimer H. | 2019-01-01 | THE LANCET. HAEMATOLOGY | - | 1.01 Articolo in rivista | - |